These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24525546)

  • 1. Fibroblast growth factor-23 and cardiac structure and function.
    Agarwal I; Ide N; Ix JH; Kestenbaum B; Lanske B; Schiller NB; Whooley MA; Mukamal KJ
    J Am Heart Assoc; 2014 Feb; 3(1):e000584. PubMed ID: 24525546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
    Mitsnefes MM; Betoko A; Schneider MF; Salusky IB; Wolf MS; Jüppner H; Warady BA; Furth SL; Portale AA
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):45-52. PubMed ID: 29025789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD.
    Smith K; deFilippi C; Isakova T; Gutiérrez OM; Laliberte K; Seliger S; Kelley W; Duh SH; Hise M; Christenson R; Wolf M; Januzzi J
    Am J Kidney Dis; 2013 Jan; 61(1):67-73. PubMed ID: 22883134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between circulating FGF23, α-Klotho, and left ventricular diastolic dysfunction among patients with preserved ejection fraction.
    Okamoto Y; Fujita S; Morita H; Kizawa S; Ito T; Sakane K; Sohmiya K; Hoshiga M; Ishizaka N
    Heart Vessels; 2016 Jan; 31(1):66-73. PubMed ID: 25223536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification.
    Scialla JJ; Lau WL; Reilly MP; Isakova T; Yang HY; Crouthamel MH; Chavkin NW; Rahman M; Wahl P; Amaral AP; Hamano T; Master SR; Nessel L; Chai B; Xie D; Kallem RR; Chen J; Lash JP; Kusek JW; Budoff MJ; Giachelli CM; Wolf M;
    Kidney Int; 2013 Jun; 83(6):1159-68. PubMed ID: 23389416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between FGF23, α-Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages.
    Tanaka S; Fujita S; Kizawa S; Morita H; Ishizaka N
    PLoS One; 2016; 11(7):e0156860. PubMed ID: 27400031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis.
    Seeherunvong W; Abitbol CL; Chandar J; Rusconi P; Zilleruelo GE; Freundlich M
    Pediatr Nephrol; 2012 Nov; 27(11):2129-2136. PubMed ID: 22710695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease.
    Seifert ME; de Las Fuentes L; Ginsberg C; Rothstein M; Dietzen DJ; Cheng SC; Ross W; Windus D; Dávila-Román VG; Hruska KA
    Am J Nephrol; 2014; 39(5):392-9. PubMed ID: 24818573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased left ventricular mass and decreased left ventricular systolic function have independent pathways to ventricular arrhythmogenesis in coronary artery disease.
    Reinier K; Dervan C; Singh T; Uy-Evanado A; Lai S; Gunson K; Jui J; Chugh SS
    Heart Rhythm; 2011 Aug; 8(8):1177-82. PubMed ID: 21376836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.
    Gutiérrez OM; Januzzi JL; Isakova T; Laliberte K; Smith K; Collerone G; Sarwar A; Hoffmann U; Coglianese E; Christenson R; Wang TJ; deFilippi C; Wolf M
    Circulation; 2009 May; 119(19):2545-52. PubMed ID: 19414634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmatic Klotho and FGF23 Levels as Biomarkers of CKD-Associated Cardiac Disease in Type 2 Diabetic Patients.
    Silva AP; Mendes F; Carias E; Gonçalves RB; Fragoso A; Dias C; Tavares N; Café HM; Santos N; Rato F; Leão Neves P; Almeida E
    Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30934737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension.
    Paoletti E; De Nicola L; Gabbai FB; Chiodini P; Ravera M; Pieracci L; Marre S; Cassottana P; Lucà S; Vettoretti S; Borrelli S; Conte G; Minutolo R
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):271-9. PubMed ID: 26668021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension and Organ Damage in Women.
    Muiesan ML; Paini A; Aggiusti C; Bertacchini F; Rosei CA; Salvetti M
    High Blood Press Cardiovasc Prev; 2018 Sep; 25(3):245-252. PubMed ID: 29943358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening.
    Xanthakis V; Larson MG; Wollert KC; Aragam J; Cheng S; Ho J; Coglianese E; Levy D; Colucci WS; Michael Felker G; Benjamin EJ; Januzzi JL; Wang TJ; Vasan RS
    J Am Heart Assoc; 2013 Nov; 2(6):e000399. PubMed ID: 24200688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiological impact of serum fibroblast growth factor 23 in patients with nonischemic cardiac disease and early chronic kidney disease.
    Imazu M; Takahama H; Asanuma H; Funada A; Sugano Y; Ohara T; Hasegawa T; Asakura M; Kanzaki H; Anzai T; Kitakaze M
    Am J Physiol Heart Circ Physiol; 2014 Nov; 307(10):H1504-11. PubMed ID: 25217649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cystatin C level is associated with left atrial enlargement, left ventricular hypertrophy and impaired left ventricular relaxation in patients with stage 2 or 3 chronic kidney disease.
    Sakuragi S; Ichikawa K; Yamada K; Tanimoto M; Miki T; Otsuka H; Yamamoto K; Kawamoto K; Katayama Y; Tanakaya M; Ito H
    Int J Cardiol; 2015; 190():287-92. PubMed ID: 25932809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS).
    Mathew JS; Sachs MC; Katz R; Patton KK; Heckbert SR; Hoofnagle AN; Alonso A; Chonchol M; Deo R; Ix JH; Siscovick DS; Kestenbaum B; de Boer IH
    Circulation; 2014 Jul; 130(4):298-307. PubMed ID: 24920722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGF23 induces left ventricular hypertrophy.
    Faul C; Amaral AP; Oskouei B; Hu MC; Sloan A; Isakova T; Gutiérrez OM; Aguillon-Prada R; Lincoln J; Hare JM; Mundel P; Morales A; Scialla J; Fischer M; Soliman EZ; Chen J; Go AS; Rosas SE; Nessel L; Townsend RR; Feldman HI; St John Sutton M; Ojo A; Gadegbeku C; Di Marco GS; Reuter S; Kentrup D; Tiemann K; Brand M; Hill JA; Moe OW; Kuro-O M; Kusek JW; Keane MG; Wolf M
    J Clin Invest; 2011 Nov; 121(11):4393-408. PubMed ID: 21985788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kansas City Cardiomyopathy Questionnaire Score Is Associated With Incident Heart Failure Hospitalization in Patients With Chronic Kidney Disease Without Previously Diagnosed Heart Failure: Chronic Renal Insufficiency Cohort Study.
    Mishra RK; Yang W; Roy J; Anderson AH; Bansal N; Chen J; DeFilippi C; Delafontaine P; Feldman HI; Kallem R; Kusek JW; Lora CM; Rosas SE; Go AS; Shlipak MG;
    Circ Heart Fail; 2015 Jul; 8(4):702-8. PubMed ID: 25985796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation.
    Seiler S; Cremers B; Rebling NM; Hornof F; Jeken J; Kersting S; Steimle C; Ege P; Fehrenz M; Rogacev KS; Scheller B; Böhm M; Fliser D; Heine GH
    Eur Heart J; 2011 Nov; 32(21):2688-96. PubMed ID: 21733911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.